<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37443258</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1348-4214</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Hypertension research : official journal of the Japanese Society of Hypertension</Title><ISOAbbreviation>Hypertens Res</ISOAbbreviation></Journal><ArticleTitle>Microvascular hypertensive disease, Long COVID, and end-organ pathology.</ArticleTitle><Pagination><StartPage>2247</StartPage><EndPage>2248</EndPage><MedlinePgn>2247-2248</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41440-023-01205-1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cimolai</LastName><ForeName>Nevio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, The University of British Columbia and, Children's and Women's Health Centre of British Columbia, 4480 Oak Street, Vancouver, BC, V6H3V4, Canada. ncimolai@mail.ubc.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hypertens Res</MedlineTA><NlmUniqueID>9307690</NlmUniqueID><ISSNLinking>0916-9636</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Hypertens Res. 2023 Sep;46(9):2249-2250. doi: 10.1038/s41440-023-01371-2</RefSource><PMID Version="1">37443263</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Microvascular</Keyword><Keyword MajorTopicYN="N">Pathology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>13</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>13</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37443258</ArticleId><ArticleId IdType="doi">10.1038/s41440-023-01205-1</ArticleId><ArticleId IdType="pii">10.1038/s41440-023-01205-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cimolai N. Mast cell biology and linkages for non-clonal mast cell activation and autoimmune/inflammatory syndrome induced by adjuvants. SN Compr Clin Med. 2020;2:2310&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-020-00494-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimolai N. Cerebral microvascular and macrovascular disease risk factors and COVID-19 progression. Cerebrovasc Dis. 2021;30:105519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2020.105519</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia JH, Ho K-L. Pathology of hypertensive arteriopathy. Neurosurg Clin N Am. 1992;3:497&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1042-3680(18)30641-7</ArticleId><ArticleId IdType="pubmed">1633473</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaoka-Tojo M. Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19. Biomed J 2020;43:399&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2020.08.007</ArticleId><ArticleId IdType="pubmed">33032965</ArticleId><ArticleId IdType="pmc">7443638</ArticleId></ArticleIdList></Reference><Reference><Citation>Canale MP, Menghini R, Martelli E, Federici M. COVID-19-associated endothelial dysfunction and microvascular injury: from pathophysiology to clinical manifestations. Card Electrophysiol Clin. 2022;14:21&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccep.2021.10.003</ArticleId><ArticleId IdType="pubmed">35221082</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornhammar P, Jernberg T, Bergstr&#xf6;m G, Blomberg A, Engstr&#xf6;m G, Engvall J, et al. Association of cardiometabolic risk factors with hospitalization or death due to COVID-19: population-based cohort study in Sweden. BMJ Open. 2021;11:e051359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-051359</ArticleId><ArticleId IdType="pubmed">34475186</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahey GM, McDonald E, Marshall K, Martin SW, Chun H, Hewlihy R, et al. Risk factors for hospitalization among persons with COVID-19: Colorado. PLoS One. 2021;16:e0256917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0256917</ArticleId><ArticleId IdType="pubmed">34473791</ArticleId><ArticleId IdType="pmc">8412293</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimolai N. Untangling the intricacies of infection, thrombosis, vaccination, and antiphospholipid antibodies for COVID-19. SN Compr Clin Med. 2021;3:2093&#x2013;2108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-021-00992-3</ArticleId><ArticleId IdType="pubmed">34179695</ArticleId><ArticleId IdType="pmc">8218573</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>